Rtw Investments
Latest statistics and disclosures from Rtw Investments's latest quarterly 13F-HR filing:
- Top 5 stock holdings are MDGL, ARGX, NTRA, AXSM, PTCT, and represent 32.01% of Rtw Investments's stock portfolio.
- Added to shares of these 10 stocks: VRNA (+$85M), GMED (+$80M), SYK (+$70M), ZLAB (+$66M), XNCR (+$42M), AKRO (+$26M), ALKS (+$26M), RAPT (+$19M), PEN (+$16M), QURE (+$16M).
- Started 9 new stock positions in RAPT, VRNA, CMPS, IMVT, Ceribell, GMED, CRVS, ZLAB, PEPG.
- Reduced shares in these 10 stocks: GERN (-$200M), MASI (-$129M), ACAD (-$92M), BRKR (-$59M), GKOS (-$50M), DYN (-$38M), IMTX (-$25M), TEM (-$23M), INSM (-$18M), SAGE (-$14M).
- Sold out of its positions in GERN, GKOS, SABS, TEM, TXG.
- Rtw Investments was a net seller of stock by $-127M.
- Rtw Investments has $6.6B in assets under management (AUM), dropping by -4.32%.
- Central Index Key (CIK): 0001493215
Tip: Access up to 7 years of quarterly data
Positions held by Rtw Investments consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Rtw Investments
Rtw Investments holds 72 positions in its portfolio as reported in the December 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Madrigal Pharmaceuticals (MDGL) | 9.3 | $615M | 2.0M | 308.57 |
|
|
| Argenx Se Sponsored Adr (ARGX) | 6.3 | $414M | +2% | 674k | 615.00 |
|
| Natera (NTRA) | 6.2 | $411M | 2.6M | 158.30 |
|
|
| Axsome Therapeutics (AXSM) | 5.2 | $343M | -3% | 4.1M | 84.61 |
|
| Ptc Therapeutics I (PTCT) | 5.0 | $334M | 7.4M | 45.14 |
|
|
| Avidity Biosciences Ord (RNA) | 3.5 | $231M | -2% | 7.9M | 29.08 |
|
| Rocket Pharmaceuticals (RCKT) | 3.4 | $222M | 18M | 12.57 |
|
|
| Alkermes SHS (ALKS) | 3.3 | $217M | +13% | 7.6M | 28.76 |
|
| Stryker Corporation (SYK) | 3.2 | $213M | +48% | 590k | 360.05 |
|
| Protagonist Therapeutics (PTGX) | 3.2 | $212M | 5.5M | 38.60 |
|
|
| Insmed Com Par $.01 (INSM) | 3.1 | $208M | -7% | 3.0M | 69.04 |
|
| Penumbra (PEN) | 3.1 | $205M | +8% | 863k | 237.48 |
|
| Akero Therapeutics (AKRO) | 2.9 | $191M | +15% | 6.9M | 27.82 |
|
| Tarsus Pharmaceuticals (TARS) | 2.7 | $179M | -5% | 3.2M | 55.37 |
|
| Merus N V (MRUS) | 2.7 | $175M | 4.2M | 42.05 |
|
|
| ACADIA Pharmaceuticals (ACAD) | 2.4 | $160M | -36% | 8.7M | 18.35 |
|
| Bruker Corporation (BRKR) | 2.2 | $145M | -28% | 2.5M | 58.62 |
|
| Immunocore Hldgs Ads (IMCR) | 2.2 | $144M | 4.9M | 29.50 |
|
|
| RadNet (RDNT) | 2.1 | $138M | +9% | 2.0M | 69.84 |
|
| Cytokinetics Com New (CYTK) | 1.9 | $128M | 2.7M | 47.04 |
|
|
| Dyne Therapeutics (DYN) | 1.9 | $123M | -23% | 5.2M | 23.56 |
|
| Apogee Therapeutics (APGE) | 1.9 | $123M | 2.7M | 45.30 |
|
|
| Establishment Labs Holdings Ord (ESTA) | 1.8 | $118M | -2% | 2.6M | 46.07 |
|
| Masimo Corporation (MASI) | 1.7 | $113M | -53% | 683k | 165.30 |
|
| Verona Pharma Sponsored Ads (VRNA) | 1.3 | $85M | NEW | 1.8M | 46.44 |
|
| Spyre Therapeutics Com New (SYRE) | 1.3 | $84M | +11% | 3.6M | 23.28 |
|
| Ultragenyx Pharmaceutical (RARE) | 1.3 | $83M | 2.0M | 42.07 |
|
|
| Globus Med Cl A (GMED) | 1.2 | $80M | NEW | 972k | 82.71 |
|
| Zai Lab Adr (ZLAB) | 1.0 | $66M | NEW | 2.5M | 26.19 |
|
| Arvinas Ord (ARVN) | 1.0 | $64M | +19% | 3.3M | 19.17 |
|
| Cargo Therapeutics (CRGX) | 0.9 | $60M | 4.1M | 14.42 |
|
|
| 89bio (ETNB) | 0.9 | $59M | 7.5M | 7.82 |
|
|
| Stoke Therapeutics (STOK) | 0.9 | $57M | +10% | 5.1M | 11.03 |
|
| Xencor (XNCR) | 0.8 | $55M | +317% | 2.4M | 22.98 |
|
| Cg Oncology (CGON) | 0.7 | $49M | +26% | 1.7M | 28.68 |
|
| Immatics SHS (IMTX) | 0.7 | $47M | -34% | 6.5M | 7.11 |
|
| Urogen Pharma (URGN) | 0.6 | $41M | 3.8M | 10.65 |
|
|
| Oruka Therapeutics (ORKA) | 0.6 | $38M | +5% | 1.9M | 19.39 |
|
| Health Sciences Acq Corp 2 (OBIO) | 0.5 | $33M | 8.2M | 4.00 |
|
|
| Neurogene (NGNE) | 0.5 | $31M | +18% | 1.4M | 22.86 |
|
| Replimune Group (REPL) | 0.4 | $25M | +82% | 2.1M | 12.11 |
|
| Lenz Therapeutics (LENZ) | 0.4 | $25M | 863k | 28.87 |
|
|
| Gh Research Ordinary Shares (GHRS) | 0.4 | $23M | 3.3M | 7.00 |
|
|
| Cullinan Oncology (CGEM) | 0.3 | $21M | 1.7M | 12.18 |
|
|
| Rapt Therapeutics (RAPT) | 0.3 | $19M | NEW | 12M | 1.58 |
|
| Roivant Sciences SHS (ROIV) | 0.3 | $17M | 1.5M | 11.83 |
|
|
| Sage Therapeutics (SAGE) | 0.2 | $16M | -46% | 3.0M | 5.43 |
|
| Uniqure Nv SHS (QURE) | 0.2 | $16M | +8936% | 904k | 17.66 |
|
| Taysha Gene Therapies Com Shs (TSHA) | 0.2 | $15M | -41% | 8.7M | 1.73 |
|
| Tourmaline Bio (TRML) | 0.2 | $15M | 737k | 20.28 |
|
|
| Dianthus Therapeutics (DNTH) | 0.2 | $15M | 667k | 21.80 |
|
|
| Corvus Pharmaceuticals (CRVS) | 0.2 | $14M | NEW | 2.7M | 5.35 |
|
| Immunovant (IMVT) | 0.2 | $13M | NEW | 531k | 24.77 |
|
| Pepgen (PEPG) | 0.2 | $12M | NEW | 3.2M | 3.79 |
|
| Compass Pathways Sponsored Ads (CMPS) | 0.2 | $12M | NEW | 3.1M | 3.78 |
|
| Wave Life Sciences SHS (WVE) | 0.2 | $11M | 900k | 12.37 |
|
|
| Perceptive Cap Solutions Cor Cl A Ord Shs (PCSC) | 0.1 | $7.6M | 743k | 10.18 |
|
|
| Exagen (XGN) | 0.1 | $6.2M | 1.5M | 4.10 |
|
|
| Milestone Pharmaceuticals (MIST) | 0.1 | $5.9M | -23% | 2.5M | 2.36 |
|
| Ideaya Biosciences (IDYA) | 0.1 | $5.1M | 200k | 25.70 |
|
|
| Immunic (IMUX) | 0.1 | $4.6M | 4.6M | 1.00 |
|
|
| Bioage Labs (BIOA) | 0.1 | $4.6M | 786k | 5.79 |
|
|
| Ceribell | 0.1 | $3.9M | NEW | 150k | 25.88 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 0.1 | $3.4M | 125k | 27.12 |
|
|
| Acelyrin (SLRN) | 0.0 | $3.1M | 978k | 3.14 |
|
|
| Regenxbio Inc equity us cm (RGNX) | 0.0 | $2.7M | 350k | 7.73 |
|
|
| Essa Pharma Com New (EPIX) | 0.0 | $2.0M | -65% | 1.1M | 1.79 |
|
| Artiva Biotherapeutics (ARTV) | 0.0 | $1.5M | 149k | 10.08 |
|
|
| Allurion Technologies Com Shs (ALUR) | 0.0 | $1.3M | -20% | 2.9M | 0.43 |
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 0.0 | $838k | 50k | 16.75 |
|
|
| Adagio Med Hldgs (ADGM) | 0.0 | $220k | 209k | 1.05 |
|
|
| Rocket Pharmaceuticals *w Exp 09/02/202 (RCKTW) | 0.0 | $12k | 350k | 0.03 |
|
Past Filings by Rtw Investments
SEC 13F filings are viewable for Rtw Investments going back to 2014
- Rtw Investments 2024 Q4 filed Feb. 14, 2025
- Rtw Investments 2024 Q3 filed Nov. 14, 2024
- Rtw Investments 2024 Q2 filed Aug. 14, 2024
- Rtw Investments 2024 Q1 filed May 15, 2024
- Rtw Investments 2023 Q4 filed Feb. 14, 2024
- Rtw Investments 2023 Q3 filed Nov. 14, 2023
- Rtw Investments 2023 Q2 filed Aug. 14, 2023
- Rtw Investments 2023 Q1 filed May 15, 2023
- Rtw Investments 2022 Q4 filed Feb. 14, 2023
- Rtw Investments 2022 Q3 filed Nov. 14, 2022
- Rtw Investments 2022 Q2 filed Aug. 15, 2022
- Rtw Investments 2022 Q1 filed May 16, 2022
- Rtw Investments 2021 Q4 filed Feb. 14, 2022
- Rtw Investments 2021 Q3 filed Nov. 15, 2021
- Rtw Investments 2021 Q2 filed Aug. 13, 2021
- Rtw Investments 2021 Q1 filed May 14, 2021